« Back
Home /
Ipriflavone (Osteofix)

Ipriflavone (Osteofix)

Item no.	S2422-5000
Manufacturer	Selleckchem
CASRN	35212-22-7
Amount	5 g
Quantity options	1 g 10 g 200 mg 5 g
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Breast Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Smiles	CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Others
Similar products	Ipriflavone
Available
Storage Conditions	2 years -80 in solvent
Molecular Weight	280, 32
Administration	Oral administration
Animal Models	Male athymic nude mice (ICR-nu/nu) injected s.c. or intracardially with MDA-231 human breast cancer cells
Cell lines	MDA-231
Concentrations	Dissolved in absolute ethanol, final concentrations ca.50 uM
Dosages	ca.12 mg/day
Formulation	Suspended in water containing 0.5% (w/v) methylcellulose
In vitro	Ipriflavone regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of some important matrix proteins and facilitating the mineralization process. [1] Ipriflavone treatment at 10 uM significantly inhibits advanced glycation end products (AGE) enhanced bone resorption in cultured mouse unfractionated bone cells. [2] In addition, Ipriflavone treatment potently enhances calcium uptake by duodenal cells. [3] Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells in a dose-dependent manner, and blocks the ligand-induced phosphorylation of Tyr845 of the EGFR. Ipriflavone treatment at 50 uM does not induce apoptosis of MDA-231 cells. [4]
In vivo	Oral administration of Ipriflavone at 12 mg but not 6 mg significantly inhibits the development of new osteolytic bone metastases of MDA-231 cells, suppresses the progression of established osteolytic lesions, and reduces the number of osteoclasts adjacent to cancer cells in bone metastases. Consistent with the in vitro activity, Ipriflavone treatment at 6 or 12 mg/day significantly inhibits tumor growth of MDA-231 xenografts with 25% and 45% reductions by volume and 47% and 63% by weight, respectively, compared to untreated mice, and prolongs the life of tumor-bearing mice. [4]
Incubation Time	24, 48, 72 and 96 hours
Method	Cells are exposed to various concentrations of Ipriflavone for 24, 48, 72 and 96 hours. Cells are treated with trypan blue to estimate the number of viable cells. For thymidine incorporation analysis, [3H]Thymidine (1 uCi) is added, and cells are harvested onto glass fiber filters 4 hours later. Radioactivity is determined by scintillation counting.
Information	Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S2422-5000-datasheet.pdf

S2422-5000-safety-datasheet.pdf